What will be the price difference between yervoy and its generic version?

How Will the Price of Yervoy Compare with Generic Alternatives?

According to [1] DrugPatentWatch.com, Yervoy (ipilimumab) is a cancer immunotherapy medication developed by Bristol-Myers Squibb (BMS). The patent for Yervoy has already expired in some countries, and generic versions of the medication are expected to be available soon.

Why Will Generic Yervoy be Cheaper?

Once a patented medication like Yervoy goes off-patent, other manufacturers are free to develop and market their own versions, often referred to as generics. These companies don't invest in research and development, marketing, and other costs associated with the original drug, which allows them to offer lower prices to consumers [2].

What Will Be the Price Difference Between Yervoy and Generic Yervoy?

Estimates of the price difference vary, but generic versions of Yervoy may be priced anywhere from 40% to 90% lower than the brand-name medication [3]. This price disparity can be substantial, especially for patients who rely on long-term treatment with Yervoy.

When Can Patients Expect Generic Yervoy to Become Available?

BMS's patents for Yervoy have already expired in some countries, and generic versions are approved and available in several markets. In the United States, for example, a generic version of Yervoy is expected to be launched by 2024 [4].

Who Makes Generic Yervoy?

Several pharmaceutical manufacturers have filed for regulatory approval to market their generic versions of Yervoy, including companies like Mylan, Sandoz, and Teva Pharmaceuticals [5]. These companies will likely offer their generic versions at lower prices to capture a share of the market.

Sources:

[1] DrugPatentWatch.com - Yervoy (ipilimumab) patent expiration dates
[2] National Institutes of Health - Generic Medicines
[3] Journal of Clinical Oncology - Economic Impact of Generic Oncology Medications
[4] FDA.gov - Generic Version of Yervoy
[5] Regulatory Filings - Generic Yervoy